SCHEMBL3537665

SCHEMBL3537665

CC1CCN(c2cc(N3CCOCC3)ccc2[N+](=O)[O-])CC1

nearest known ligand 0.73

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 18/20 0.73
ALDH1A1 P00352 13/20 0.73
NPSR1 Q6W5P4 2/20 0.73
SMN1; SMN2 Q16637 2/20 0.73
CYP2C9 P11712 2/20 0.67
LMNA P02545 5/20 0.67
GAA P10253 1/20 0.67
HTT P42858 1/20 0.67
HPGD P15428 1/20 0.66
CYP2C19 P33261 2/20 0.60
CYP1A2 P05177 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
PKM P14618 1/20 0.59
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
NPC1 O15118 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31000430 0.86 ALDH1A1 (0.74) MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9
SCHEMBL3541105 0.86 ALDH1A1 (0.74) MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9
SCHEMBL3540722 0.85 MAPT (0.73) MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9
SCHEMBL2484504 0.85 MAPT (0.76) MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9
SCHEMBL6499616 0.84 MAPT (0.81) MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9
SCHEMBL30501456 0.84 MAPT (1.00) MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9
SCHEMBL3537969 0.84 MAPT (1.00) MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9
SCHEMBL31000451 0.82 MAPT (0.73) MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9
SCHEMBL27691387 0.82 MAPT (0.56) MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9
SCHEMBL28766651 0.81 MAPT (0.55) MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
CN-101084208-A Aromatic amides as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2007-12-05 CN disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES MAPT 159/4885ALDH1A1 4796/4885NPSR1 329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.